Physician profile
Steven Patrick Clancy
NPI 1619966504
$1,765.31
in general payments reported to CMS, 2019-2025
18 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.57 · 2020: $91.01 · 2021: $320 · 2022: $557 · 2023: $272 · 2024: $273 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.63 | 2022-2025 | Durysta, Vuity, Alphagan P |
| Allergan, INC. | $170.40 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $153.89 | 2022-2023 | Catalys System, Tecnis Simplicity |
| Alcon Vision LLC | $151.62 | 2019-2024 | Clareon |
| Glaukos Corporation | $135.45 | 2022-2024 | Idose |
| Aerie Pharmaceuticals, INC. | $124.01 | 2021 | |
| Kala Pharmaceuticals, INC. | $122.79 | 2022 | |
| Astellas Pharma US INC | $97.41 | 2024 | Izervay |
| Optovue, INC. | $91.01 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $75.05 | 2025 | Xdemvy |
| Topcon Healthcare, INC. | $74.68 | 2025 | |
| Oyster Point Pharma, INC. | $45.16 | 2022-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $30.91 | 2023 | Acthar |
| Dompe US, INC. | $27.28 | 2025 | Oxervate |
| Thea Pharma INC. | $18.89 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $18.07 | 2024 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Bausch & Lomb Americas INC. | $14.76 | 2024 | Vyzulta, Miebo |
| Horizon Therapeutics Plc | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Clancy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.